A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Abroad (travel likely)RecruitingPHASE2

Conditions

High-Risk Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
Contact: Study coordinator (Matthew B Rettig, MD) · Matthew.rettig@va.gov · 310-478-3711
Contact: Study coordinator (Samantha M Tran) · Samantha.Tran@va.gov · 3104783711
James J. Peters VA Medical Center, Bronx, NY, The Bronx, New York, United States
Contact: Study coordinator (Izak Faiena, MD) · izak.faiena@va.gov
Contact: Study coordinator (Amelia Kiliveros) · amelia.kiliveros@va.gov
VA Portland Health Care System, Portland, OR, Portland, Oregon, United States
Contact: Study coordinator (Ryan P Kopp, MD) · ryan.kopp@va.gov · 503-220-8262
Contact: Study coordinator (Laura Onstad, RN) · laura.onstad@va.gov · (503) 721-1060
Contact: Principal Investigator (Ryan P Kopp, MD)
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States
Contact: Study coordinator (Steven Savage, MD) · 843-789-7816
Contact: Study coordinator (Elina Bolukbasi, RN) · 8435775011
South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
Contact: Study coordinator (Robert B Montgomery, MD) · rbmontgo@uw.edu · 206-277-6878
Contact: Study coordinator (Makayla L Dejong) · Makayla.Dejong@va.gov · 2062774527

Study leads

Ryan P Kopp, MD
Principal Investigator
VA Portland Health Care System, Portland, OR

View source on ClinicalTrials.gov Contact study team (email)